• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    Trian Comments on Solventum's Sale of its Purification & Filtration Business

    2/26/25 2:50:51 PM ET
    $SOLV
    $TMO
    Medical/Dental Instruments
    Health Care
    Industrial Machinery/Components
    Industrials
    Get the next $SOLV alert in real time by email

    NEW YORK, Feb. 26, 2025 (GLOBE NEWSWIRE) -- Trian Fund Management, L.P. ("Trian"), which beneficially owns ~5% of Solventum Corporation (NYSE:SOLV) ("Solventum" or the "Company") and is the Company's largest active shareholder, commented on Solventum's recently announced sale of its Purification & Filtration business to Thermo Fisher Scientific Inc (NYSE:TMO) ("Thermo Fisher"). Trian issued the following statement:

    "Trian commends Solventum on the announced sale of its Purification & Filtration business and believes this is an important first step in the Company's value creation journey. We believe that part of what attracted strategic interest at such a high valuation multiple was the division's differentiated technology and material science – attributes inherited from 3M which are present at Solventum's remaining businesses, and which we believe remain underappreciated by the market today.

    Notably, in conjunction with the acquisition, Thermo Fisher issued public comments which Trian believes confirm that there is a meaningful cost reduction opportunity at Solventum:

    "Excluding financing costs, the transaction is expected to be accretive by $0.28 in that period. This reflects the very strong day one cost synergies when Solventum's allocated segment costs are replaced by lower run rate costs within Thermo Fisher."

    Thermo Fisher's release goes on to suggest that it believes it can more than double the profitability of Purification & Filtration under its corporate umbrella, relative to the business' current profit as part of Solventum, with much of that improvement driven by lower allocated costs.

    Trian, in its January letter to shareholders, highlighted that Solventum has a significant opportunity to right size costs and realize higher margins while reinvesting more in growth.

    Inside of 3M, Solventum averaged 3-4% organic growth and a 26-27% EBIT margin. Trian believes that Solventum should be able to deliver faster organic growth and higher margins as a focused, standalone company. Trian looks forward to the Company delivering a Long Range Plan that reflects the business' potential when it hosts its investor day in March."

    About Trian Fund Management, L.P.

    Founded in 2005, Trian Fund Management, L.P. ("Trian") is a multi-billion dollar investment management firm. Trian is a highly engaged shareowner that combines concentrated public equity ownership with operational expertise. Leveraging the 50+ years' operating experience of our Founding Partners, Nelson Peltz and Peter May, Trian seeks to invest in high quality but undervalued and underperforming public companies and to work collaboratively with management teams and boards to help companies execute operational and strategic initiatives designed to drive long-term sustainable earnings growth for the benefit of all shareholders.

    Media Contacts:

    Anne A. Tarbell

    (212) 451-3030

    [email protected]

    Paul Caminiti / Pamela Greene / Jacqueline Zuhse

    Reevemark

    (212) 433-4600

    [email protected]

    Investor Contact:

    Matt Underhill

    (212) 451-3171

    [email protected]

    Disclaimer

    Except as otherwise set forth in this press release, the views expressed in this press release reflect the opinions of Trian Fund Management, L.P. and its affiliates ("Trian"), and are based on publicly available information with respect to Solventum Corporation (the "Company"). Trian recognizes that there may be confidential information in the possession of the Company that could lead it or others to disagree with Trian's conclusions. Trian reserves the right to change any of its opinions expressed herein at any time as it deems appropriate and disclaims any obligation to notify the market or any other party of any such change, except as required by law. Trian disclaims any obligation to update the information or opinions contained in this press release. For the avoidance of doubt, this press release is not affiliated with or endorsed by the Company.

    This press release is provided merely as information and is not intended to be, nor should it be construed as, an offer to sell or a solicitation of an offer to buy any security nor as a recommendation to purchase or sell any security. Funds managed by Trian currently beneficially own shares of the Company. These funds are in the business of trading – buying and selling– securities and intend to continue trading in the securities of the Company. You should assume such funds may from time to time sell all or a portion of their holdings of the Company in open market transactions or otherwise (including via short sales), buy additional shares (in open market or privately negotiated transactions or otherwise), or trade in options, puts, calls, swaps or other derivative instruments relating to such shares.

    Some of the materials in this press release contain forward-looking statements. All statements contained herein that are not clearly historical in nature or that necessarily depend on future events are forward-looking, and the words "anticipate," "believe," "expect," "potential," "could," "opportunity," "estimate," "plan," and similar expressions are generally intended to identify forward-looking statements. The projected results and statements contained herein that are not historical facts are based on current expectations, speak only as of the date of these materials and involve risks, uncertainties and other factors that may cause actual results, performances or achievements to be materially different from any future results, performances or achievements expressed or implied by such projected results and statements. Assumptions relating to the foregoing involve judgments with respect to, among other things, future economic competitive and market conditions and future business decisions, all of which are difficult or impossible to predict accurately and many of which are beyond the control of Trian.

    Certain financial projections and statements made herein have been derived or obtained from filings made with the Securities and Exchange Commission ("SEC") or other regulatory authorities and from other third-party reports. Trian shall not be responsible or have any liability for any misinformation contained in any third-party, SEC or other regulatory filing or third-party report.

    There is no assurance or guarantee with respect to the prices at which any securities of the Company will trade, and such securities may not trade at prices that may be implied herein. The estimates, projections and potential impact of the opportunities identified by Trian herein are based on assumptions that Trian believes to be reasonable as of the date of this press release, but there can be no assurance or guarantee (i) that any of the proposed actions set forth in this press release will be completed, (ii) that the actual results or performance of the Company will not differ, and such differences may be material, or (iii) that any of the assumptions provided in this press release are accurate.  This press release does not recommend the purchase or sale of any security.



    Primary Logo

    Get the next $SOLV alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $SOLV
    $TMO

    CompanyDatePrice TargetRatingAnalyst
    Thermo Fisher Scientific Inc
    $TMO
    1/10/2025$630.00Mkt Perform → Outperform
    Bernstein
    Thermo Fisher Scientific Inc
    $TMO
    12/23/2024Sector Perform
    Scotiabank
    Solventum Corporation
    $SOLV
    12/4/2024$70.00Neutral
    Mizuho
    Thermo Fisher Scientific Inc
    $TMO
    10/14/2024Buy
    Redburn Atlantic
    Solventum Corporation
    $SOLV
    10/8/2024$82.00Buy
    Stifel
    Solventum Corporation
    $SOLV
    10/7/2024$71.00Neutral
    Piper Sandler
    Thermo Fisher Scientific Inc
    $TMO
    10/1/2024$680.00Overweight
    Stephens
    Solventum Corporation
    $SOLV
    9/26/2024Peer Perform
    Wolfe Research
    More analyst ratings

    $SOLV
    $TMO
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Solventum Reports First Quarter 2025 Financial Results

      Reported sales increased 2.6%; organic sales increased 4.3%Increases full year organic sales growth outlook by 50 bps to +1.5% to +2.5%ST. PAUL, Minn., May 8, 2025 /PRNewswire/ -- Solventum (NYSE:SOLV) today reported financial results for the first quarter ended March 31, 2025. First Quarter 2025 Highlights Sales increased 2.6% to $2.1 billion; up 4.3% on an organic basisGAAP diluted earnings per share of $0.78; adjusted diluted earnings per share of $1.34Operating cash flow of $29 million; free cash flow of $(80) million"Our first quarter fiscal year 2025 results reflect soli

      5/8/25 4:05:00 PM ET
      $SOLV
      Medical/Dental Instruments
      Health Care
    • Solventum to Participate in the 2025 BofA Securities Health Care Conference

      ST. PAUL, Minn., May 8, 2025 /PRNewswire/ -- Solventum (NYSE:SOLV) announced today its executives will participate in a fireside chat at the 2025 BofA Securities Health Care Conference on Tuesday, May 13, 2025, beginning at approximately 2:20 p.m. PST in Las Vegas, NV. A live and archived replay of the fireside chat will be available on the company's website at investors.solventum.com. About SolventumAt Solventum, we enable better, smarter, safer healthcare to improve lives. As a new company with a long legacy of creating breakthrough solutions for our customers' toughest chal

      5/8/25 4:05:00 PM ET
      $SOLV
      Medical/Dental Instruments
      Health Care
    • Thermo Fisher Scientific to Present at BofA Securities 2025 Health Care Conference on May 13

      Thermo Fisher Scientific Inc. (NYSE:TMO), the world leader in serving science, announced that Marc N. Casper, chairman, president and chief executive officer, will present at the BofA Securities Health Care Conference on Tuesday, May 13, 2025 at 11:40 a.m. (ET). The live webcast of the presentation can be accessed via the Investors section of our website, www.thermofisher.com. About Thermo Fisher Scientific Thermo Fisher Scientific Inc. is the world leader in serving science, with annual revenue over $40 billion. Our Mission is to enable our customers to make the world healthier, cleaner and safer. Whether our customers are accelerating life sciences research, solving complex analytical

      5/6/25 8:00:00 AM ET
      $TMO
      Industrial Machinery/Components
      Industrials

    $SOLV
    $TMO
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Thermo Fisher upgraded by Bernstein with a new price target

      Bernstein upgraded Thermo Fisher from Mkt Perform to Outperform and set a new price target of $630.00

      1/10/25 8:42:46 AM ET
      $TMO
      Industrial Machinery/Components
      Industrials
    • Scotiabank initiated coverage on Thermo Fisher

      Scotiabank initiated coverage of Thermo Fisher with a rating of Sector Perform

      12/23/24 8:24:48 AM ET
      $TMO
      Industrial Machinery/Components
      Industrials
    • Mizuho initiated coverage on Solventum Corporation with a new price target

      Mizuho initiated coverage of Solventum Corporation with a rating of Neutral and set a new price target of $70.00

      12/4/24 7:49:27 AM ET
      $SOLV
      Medical/Dental Instruments
      Health Care

    $SOLV
    $TMO
    SEC Filings

    See more
    • SEC Form 10-Q filed by Solventum Corporation

      10-Q - Solventum Corp (0001964738) (Filer)

      5/9/25 12:24:15 PM ET
      $SOLV
      Medical/Dental Instruments
      Health Care
    • Solventum Corporation filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

      8-K - Solventum Corp (0001964738) (Filer)

      5/8/25 4:13:51 PM ET
      $SOLV
      Medical/Dental Instruments
      Health Care
    • Solventum Corporation filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders

      8-K - Solventum Corp (0001964738) (Filer)

      5/2/25 4:12:15 PM ET
      $SOLV
      Medical/Dental Instruments
      Health Care

    $SOLV
    $TMO
    Leadership Updates

    Live Leadership Updates

    See more
    • GeminiBio Appoints Mike Stella to Board

      Strengthening Board with Industry Veterans Gemini Bioproducts, LLC ("GeminiBio"), a biopharma and advanced therapy raw materials supplier, and a portfolio company of BelHealth Investment Partners, LLC ("BelHealth"), a Fort Lauderdale-based healthcare private equity firm, announced today the appointment of Michael Stella to its Board of Directors. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250218608576/en/Mike Stella, CEO of Ascend Advanced Therapies, joins the Board at GeminiBio to provide strategic leadership in the fields of cell and gene therapy contract development and manufacturing. (Photo: Business Wire) GeminiBio prov

      2/18/25 9:00:00 AM ET
      $AMGN
      $GSK
      $JNJ
      $MRK
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
      Biotechnology: Pharmaceutical Preparations
      Industrial Machinery/Components
    • Ampersand Biomedicines Appoints Elizabeth Mily to Board of Directors

      BOSTON, Feb. 11, 2025 (GLOBE NEWSWIRE) -- Ampersand Biomedicines, a multi-product platform company developing smarter medicines that act specifically at the site of disease and nowhere else, today announced the appointment of Elizabeth Mily to its Board of Directors as Independent Director. A highly respected healthcare and financial industry veteran with more than 30 years of experience, Mily brings extensive expertise in corporate strategy, business development and investment leadership to Ampersand as it advances its Address, Navigate, Determine (AND)™ Platform to develop programmed biologics. "We are thrilled to welcome Elizabeth to Ampersand's Board as we leverage our AND Platform to

      2/11/25 8:00:00 AM ET
      $SOLV
      Medical/Dental Instruments
      Health Care
    • The T1D Fund Appoints Industry Veteran Elizabeth Mily as CEO to Accelerate Development of Type 1 Diabetes Cures Through Impact Investing

      Former Bristol Myers Squibb, Goldman Sachs, and Barclays executive brings deep expertise in corporate strategy, partnership development, public and private financial markets, and management as the organization evolves its leadership and investment strategy Appointment signals plans to capitalize on previous success and maximize impact by expanding equity investments and partnerships with venture capital, large biopharma, and key foundations with a proven team leader and dealmaker BOSTON, Jan. 8, 2025 /PRNewswire/ -- The T1D Fund, an impact investment fund with a focus on accelerating life-changing solutions to treat, prevent, and cure type 1 diabetes (T1D), today announced it appointed Eliza

      1/8/25 6:30:00 AM ET
      $SOLV
      Medical/Dental Instruments
      Health Care

    $SOLV
    $TMO
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Solventum Corporation

      SC 13G/A - Solventum Corp (0001964738) (Subject)

      11/12/24 5:47:11 PM ET
      $SOLV
      Medical/Dental Instruments
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Solventum Corporation

      SC 13G/A - Solventum Corp (0001964738) (Subject)

      11/4/24 1:47:43 PM ET
      $SOLV
      Medical/Dental Instruments
      Health Care
    • SEC Form SC 13G/A filed by Thermo Fisher Scientific Inc (Amendment)

      SC 13G/A - THERMO FISHER SCIENTIFIC INC. (0000097745) (Subject)

      2/9/23 11:35:13 AM ET
      $TMO
      Industrial Machinery/Components
      Industrials

    $SOLV
    $TMO
    Financials

    Live finance-specific insights

    See more
    • Solventum Reports First Quarter 2025 Financial Results

      Reported sales increased 2.6%; organic sales increased 4.3%Increases full year organic sales growth outlook by 50 bps to +1.5% to +2.5%ST. PAUL, Minn., May 8, 2025 /PRNewswire/ -- Solventum (NYSE:SOLV) today reported financial results for the first quarter ended March 31, 2025. First Quarter 2025 Highlights Sales increased 2.6% to $2.1 billion; up 4.3% on an organic basisGAAP diluted earnings per share of $0.78; adjusted diluted earnings per share of $1.34Operating cash flow of $29 million; free cash flow of $(80) million"Our first quarter fiscal year 2025 results reflect soli

      5/8/25 4:05:00 PM ET
      $SOLV
      Medical/Dental Instruments
      Health Care
    • Thermo Fisher Scientific Reports First Quarter 2025 Results

      Thermo Fisher Scientific Inc. (NYSE:TMO), the world leader in serving science, today reported its financial results for the first quarter ended March 29, 2025. First Quarter Highlights First quarter revenue was $10.36 billion. First quarter GAAP diluted earnings per share (EPS) grew 15% to $3.98. First quarter adjusted EPS grew 1% to $5.15. Delivered very strong financial performance in the quarter, demonstrating the strength of our trusted partner status and the power of our PPI Business System in a more uncertain macroeconomic environment. Advanced our proven growth strategy, launching a range of high-impact, innovative new products during the quarter. To transform semiconduc

      4/23/25 6:00:00 AM ET
      $TMO
      Industrial Machinery/Components
      Industrials
    • Solventum to Report First Quarter Fiscal 2025 Earnings on May 8, 2025

      ST. PAUL, Minn., April 17, 2025 /PRNewswire/ -- Solventum (NYSE:SOLV) will release its first quarter fiscal 2025 financial results on Thursday, May 8, 2025, after the U.S. financial markets close. After the release, Solventum management will host a webcast to discuss the results and its business. Other forward-looking and material information may also be discussed during the webcast. Earnings webcast details: Date: Thursday, May 8, 2025 Time: 3:30 p.m. CST / 4:30 p.m. EST Location: https://investors.solventum.com U.S. dial-in +1 (800) 715-9871 International dial-in: +1 (646

      4/17/25 4:05:00 PM ET
      $SOLV
      Medical/Dental Instruments
      Health Care

    $SOLV
    $TMO
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Chai Nelson sold $8,449 worth of shares (16 units at $528.09) and bought $11,038 worth of shares (20 units at $551.90), increasing direct ownership by 0.03% to 14,252 units (SEC Form 4)

      4 - THERMO FISHER SCIENTIFIC INC. (0000097745) (Issuer)

      2/21/25 4:19:32 PM ET
      $TMO
      Industrial Machinery/Components
      Industrials
    • Boxer Michael A bought $2,105 worth of shares (4 units at $526.15), increasing direct ownership by 0.03% to 13,101 units (SEC Form 4)

      4 - THERMO FISHER SCIENTIFIC INC. (0000097745) (Issuer)

      10/6/23 4:23:51 PM ET
      $TMO
      Industrial Machinery/Components
      Industrials

    $SOLV
    $TMO
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4 filed by Director Alban Carlos

      4 - Solventum Corp (0001964738) (Issuer)

      5/2/25 4:38:20 PM ET
      $SOLV
      Medical/Dental Instruments
      Health Care
    • SEC Form 4 filed by Director Cox Carrie Smith

      4 - Solventum Corp (0001964738) (Issuer)

      5/2/25 4:34:40 PM ET
      $SOLV
      Medical/Dental Instruments
      Health Care
    • SEC Form 4 filed by Director Devore Susan D.

      4 - Solventum Corp (0001964738) (Issuer)

      5/2/25 4:31:57 PM ET
      $SOLV
      Medical/Dental Instruments
      Health Care